TOLREMO THERAPEUTICS
TOLREMO therapeutics is a developer of small molecules intended to target novel drug resistance pathways in cancer therapy.The company's molecules specifically eradicate those cancer cells that cause drug resistance, enabling physicians to get personalized anti-drug resistance therapies to meaningfully prolong the lives of cancer patients.
TOLREMO THERAPEUTICS
Social Links:
Industry:
Biotechnology Pharmaceutical
Founded:
2017-01-01
Address:
Zürich, Zurich, Switzerland
Country:
Switzerland
Website Url:
http://www.tolremo.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
16.1 M CHF
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Google Tag Manager Content Delivery Network Google Universal Analytics
Similar Organizations
Carrick Therapeutics
Carrick Therapeutics is a developer of cancer therapeutics intended to transform the way cancer is treated.
Cullgen
Cullgen is a drug discovery services intended to create new drugs for the treatment of diseases that currently lack effective therapies.
Geneos Therapeutics
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
Jounce Therapeutics
Jounce Therapeutics is developing cancer immune-therapies to harness the immune system to attack cancerous cells and tumors.
Navitor Pharmaceuticals
Navitor Pharma is a developer of novel medicines designed to target specific nutrient-sensing proteins to treat diseases.
Obsidian Therapeutics
Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Current Advisors List
Current Employees Featured
Founder
Investors List
BioMedPartners
BioMedPartners investment in Series A - TOLREMO therapeutics
Altos Ventures
Altos Ventures investment in Series A - TOLREMO therapeutics
BioMedPartners
BioMedPartners investment in Series A - TOLREMO therapeutics
Zürcher Kantonal Bank
Zürcher Kantonal Bank investment in Series A - TOLREMO therapeutics
Redalpine
Redalpine investment in Series A - TOLREMO therapeutics
Newest Events participated
Official Site Inspections
http://www.tolremo.com
- Host name: 198.49.23.144
- IP address: 198.49.23.144
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
More informations about "TOLREMO therapeutics"
About Us — TOLREMO therapeutics: Stopping Non-genetic …
At TOLREMO, we address transcriptional non-oncogene addiction both as monotherapy and as combination regimens to transform targeted cancer treatments into long-term therapeutic …See details»
Tolremo - Overview, News & Competitors | ZoomInfo.com
TOLREMO Treats First Patient in Phase I Trial with TT125-802, a Novel Therapeutic Agent to Overcome Transcriptional Cancer Drug Resistance BASEL, Switzerland--(BUSINESS WIRE)- …See details»
TOLREMO therapeutics - Crunchbase Company Profile …
TOLREMO therapeutics may be growing as it has successfully completed a significant Series A financing round, securing USD 39 million in investments. …See details»
TOLREMO therapeutics AG – Swiss Biotech
TOLREMO’s vision is to meaningfully prolong the lives of cancer patients using its personalized anti-drug-resistance therapies. Products, services, technology Proprietary drug discovery and development platform to explore novel …See details»
TOLREMO therapeutics AG | EuroQuity
About your organization / profile ... TOLREMO is a privately held Swiss biotechnology company established in 2017 as a spin-off of ETH Zurich, one of the leading science and technology …See details»
TOLREMO therapeutics AG - VentureRadar
Nov 5, 2018 TOLREMO develops novel small molecules that eradicate drug resistant cancer cells right at the start of a therapy. TOLREMO’s resistance-breaking add-on therapies can be …See details»
TOLREMO therapeutics AG - top100startup.ch
Nov 14, 2020 Milestones. 08.05.2024 TOLREMO Welcomes Dr. Alan Sandler to Scientific Advisory Board; 28.11.2023 TOLREMO Treats First Patient in Phase I Trial with TT125-802, a …See details»
TOLREMO therapeutics - EU-Startups
Sep 22, 2023 TOLREMO therapeutics AG (“TOLREMO”) is a Swiss biotechnology company that was spun out of ETH Zurich in 2017. Based on cutting-edge science and guided by pioneering …See details»
TOLREMO therapeutics: Stopping Non-genetic Cancer Drug …
TOLREMO therapeutics' mission is to prevent non-genetic cancer drug resistance by dismantling the earliest defense to targeted therapies. Led by phenotypic insights, we discovered a pivotal …See details»
Tolremo Therapeutics - ACI: Advise Connect Inspire
TOLREMO was founded on pioneering expertise in non-mutational drug resistance to deliver a new wave of resistance-preventing precision therapies to patients with cancer. Our proprietary …See details»
TOLREMO therapeutics 2025 Company Profile: Valuation, Funding ...
TOLREMO therapeutics General Information Description. Operator of a biotechnology company intended to discover and develop small molecule therapies to prevent drug resistance and non …See details»
TOLREMO therapeutics AG - Venturelab
Mar 16, 2017 TOLREMO therapeutics' mission is to prevent non-genetic cancer drug resistance by dismantling the earliest defense to targeted therapies. Led by phenotypic insights, we …See details»
TOLREMO therapeutics - Funding, Financials, Valuation & Investors
TOLREMO therapeutics is a developer of small molecules intended to target novel drug resistance pathways in cancer therapy. ... Log In. Log In. Experience the new Crunchbase, …See details»
portfolio assets | tolremo - redalpine
There is an unmet need for durable therapeutic treatments for cancer patients, as current drugs often lose their effectiveness over time. drug resistance therefore remains a major limiting …See details»
News & Events — TOLREMO therapeutics: Stopping Non-genetic …
2 days ago TOLREMO Treats First Patient in Phase I Trial with TT125-802, a Novel Therapeutic Agent to Overcome Transcriptional Cancer Drug Resistance. November 28, 2023. Full text of …See details»
TOLREMO therapeutics Announces TT125-802 is the First
2 days ago TOLREMO therapeutics AG Dr. Stefanie Flückiger-Mangual, CEO and Co-founder [email protected]. Trophic Communications Dr. Stephanie May & Dr. Marie …See details»
TOLREMO therapeutics Announces TT125-802 is the First …
2 days ago TOLREMO therapeutics AG Dr. Stefanie Flückiger-Mangual, CEO and Co-founder [email protected]. Trophic Communications Dr. Stephanie May & Dr. Marie …See details»
TOLREMO Scientific Advisory Board Gallery — TOLREMO …
He is active in the European Thoracic Oncology Platform (ETOP) and the European Organization for Research and Treatment of Cancer (EORTC) Lung Group. PROFESSOR JOSEP …See details»
TOLREMO therapeutics - Contacts, Employees, Board Members
TOLREMO therapeutics is a developer of small molecules intended to target novel drug resistance pathways in cancer therapy. ... Experience the new Crunchbase, powered by AI . …See details»
Contact Us — TOLREMO therapeutics: Stopping Non-genetic …
At TOLREMO Therapeutics, we’re pioneering therapies that tackle the earliest mechanisms of non-genetic cancer drug resistance. We believe that through collaboration and sharing …See details»